Saturday 17 October 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.
22.07
0.55
−2.43%
Follow ANRO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 |
P/S ratio |
— | — | — | — | 0.00 |
P/FCF ratio |
— | — | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 10.29 |
P/Operating CF |
— | — | — | — | (6.70) |
P/B ratio |
— | — | — | — | 0.00 |
Price to Tangible BV |
— | — | — | — | 0.00 |
EV/Sales |
— | — | — | — | 0.00 |
EV/EBITDA |
— | — | — | — | 0.00 |
EV/Operating CF |
— | — | — | — | (0.14) |
EV/FCF |
— | — | — | — | (0.13) |
Quick Ratio |
15.58 | 16.81 | 14.71 | 8.75 | 15.03 |
Current Ratio |
15.69 | 16.92 | 15.22 | 8.85 | 15.30 |
Net Debt/EBITDA |
2.40 | 2.30 | 1.94 | 1.35 | 2.16 |
Debt/Assets |
10.28% | 6.51% | 11.38% | 18.61% | 0.00% |
Debt/Equity |
0.13 | 0.08 | 0.14 | 0.28 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.77 | 0.92 | 0.74 | 1.01 |
Capex/Depreciation |
(0.04) | (4.13) | (1.26) | (2.14) | (4.69) |
Interest Coverage |
(26.88) | (49.90) | (27.60) | — | — |
| (41.80%) | (153.99%) | 65.96% | 108.91% | 0.00% | |
| (34.92%) | (46.51%) | (52.81%) | (69.58%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(37.58%) | (37.92%) | (44.88%) | (61.81%) | (34.11%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 2,598.45 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 3,985.71% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 1,855.24% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 108.10% |
Graham Net Nets |
— | — | — | — | 0.89 |
Graham Number |
— | — | — | — | 0.00 |
Earnings Yield |
— | — | — | — | (47.01%) |
Free Cash Flow Yield |
— | — | — | — | (43.92%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.09 |
Operating CF per Share |
(1.79) | (1.93) | (8.96) | (5.92) | (3.84) |
Capex per Share |
0.00 | (0.08) | (0.13) | (0.21) | (0.28) |
Free Cash Flow per Share |
(1.80) | (2.01) | (9.09) | (6.13) | (4.12) |
Cash per Share |
6.12 | 6.84 | 22.12 | 14.03 | 10.65 |
Shareholders Equity per Share |
5.24 | 6.16 | 18.71 | 9.82 | 10.64 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.24 | 6.16 | 18.71 | 9.82 | 10.64 |
Free Cash Flow |
(51.79) | (49.50) | (33.92) | (21.13) | (9.94) |
Working Capital |
166.39 | 159.33 | 79.78 | 43.66 | 25.87 |
Capital Expenditures |
(0.02) | (2.07) | (0.47) | (0.73) | (0.68) |
Net Current Asset Value |
144.17 | 143.26 | 68.57 | 32.20 | 24.58 |
EV/EBIT |
— | — | — | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 3.24 |
Price to Operating Income |
— | — | — | — | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.35 | 0.19 | 0.34 | 0.29 | 0.14 |
Cash ROIC |
(14.94%) | (14.94%) | (20.91%) | (23.05%) | (19.35%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 0.17 | 0.91 | — |
Average Payables |
1.73 | 1.33 | 1.34 | 1.10 | — |
Average Assets |
181.12 | 132.09 | 68.74 | 39.82 | — |
Average Common Equity |
151.30 | 39.89 | (55.04) | (25.44) | — |
Columns are period end dates